Autoantibody profiling to follow evolution of lupus syndromes

被引:59
作者
Olsen, Nancy J. [1 ]
Li, Quan-Zhen [2 ]
Quan, Jiexia [3 ]
Wang, Ling [2 ]
Mutwally, Azza [3 ]
Karp, David R. [3 ]
机构
[1] Penn State MS Hershey Med Ctr, Dept Med, Div Rheumatol, Hershey, PA 17033 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Med, Div Rheumat Dis, Dallas, TX 75390 USA
关键词
REVISED CRITERIA; ERYTHEMATOSUS; DISEASE; DIAGNOSIS; SLE; CLASSIFICATION; ANTIBODIES; ONSET; RISK; RO;
D O I
10.1186/ar3927
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness. Methods: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined. Results: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P <= 0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 x 10(-7)) Conclusions: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care.
引用
收藏
页数:9
相关论文
共 24 条
[1]   Development of autoantibodies before the clinical onset of systemic lupus erythematosus [J].
Arbuckle, MR ;
McClain, MT ;
Rubertone, MV ;
Scofield, RH ;
Dennis, GJ ;
James, JA ;
Harley, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) :1526-1533
[2]   Clinical and laboratory aspects of Ro/SSA-52 autoantibodies [J].
Defendenti, Caterina ;
Atzeni, Fabiola ;
Spina, Maria Francesca ;
Grosso, Silvia ;
Cereda, Aldo ;
Guercilena, Giacinto ;
Bollani, Simona ;
Saibene, Simone ;
Puttini, Piercarlo Sarzi .
AUTOIMMUNITY REVIEWS, 2011, 10 (03) :150-154
[3]   SLE diagnosis and treatment: When early is early [J].
Doria, Andrea ;
Zen, Margherita ;
Canova, Mariagrazia ;
Bettio, Silvano ;
Bassi, Nicola ;
Nalotto, Linda ;
Rampudda, Mariaelisa ;
Ghirardello, Anna ;
Iaccarino, Luca .
AUTOIMMUNITY REVIEWS, 2010, 10 (01) :55-60
[4]   Dramatic development of severe SLE in a patient with an incomplete disease [J].
Fabio, G ;
Carrabba, M ;
Hu, C ;
Floriani, M ;
Besana, C .
RHEUMATOLOGY INTERNATIONAL, 2005, 25 (07) :543-547
[5]   Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms [J].
Heinlen, Latisha D. ;
McClain, Micah T. ;
Merrill, Joan ;
Akbarali, Yasmin W. ;
Edgerton, Colin C. ;
Harley, John B. ;
James, Judith A. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (07) :2344-2351
[6]   60 kD Ro and nRNP A Frequently Initiate Human Lupus Autoimmunity [J].
Heinlen, Latisha D. ;
McClain, Micah T. ;
Ritterhouse, Lauren L. ;
Bruner, Benjamin F. ;
Edgerton, Colin C. ;
Keith, Michael P. ;
James, Judith A. ;
Harley, John B. .
PLOS ONE, 2010, 5 (03)
[7]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[8]   Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus [J].
James, J. A. ;
Kim-Howard, X. R. ;
Bruner, B. F. ;
Jonsson, M. K. ;
McClain, M. T. ;
Arbuckle, M. T. ;
Walker, C. ;
Dennis, G. J. ;
Merrill, J. T. ;
Harley, J. B. .
LUPUS, 2007, 16 (06) :401-409
[9]   Prevention of autoimmune rheumatic disease: state of the art and future perspectives [J].
Klareskog, Lars ;
Gregersen, Peter K. ;
Huizinga, Tom W. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (12) :2062-2066
[10]   Autoantibody determination in the diagnosis of systemic lupus erythematosus [J].
Kurien, B. T. ;
Scofield, R. H. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2006, 64 (03) :227-235